Search by Keyword
Based on our unique and proprietary “VIPs” and polymer synthesis technologies, currently we are developing and manufacturing three categories of DNA/siRNA transfection reagents, which show distinct transfection characteristics compared with the leading products in the market. What's more important is that the transfection reagents we are manufacturing are very affordable and will save your precious research budget.
Transfection Reagent Selection Chart.
GenJet™ In Vitro DNA Tranfection Reagent (Ver. II) is upgraded version of GenJet™ In Vitro DNA Transfection Reagent. Adopting a new chemistry, more DNA condensing groups were liberated in GenJet™ (Ver. II) (100 % vs. 80% in old version), leading to 3~4 folds increase of transfection efficiency without sacrificing cell viability. GenJet™ (Ver. II) reagent, 1.0 ml, is sufficient for ~667 transfections in 24 well plates or ~333 transfections in 6 well plates.
Features compared with old version GenJet™ In Vitro DNA Trasnfection Reagent
- Cell-dependent 3~4 times higher efficiency
- Top choice for hard-to-transfect cells
- Efficiency boosted in the presence of serum and antibiotics for most of cell types
- Exceptional high levels of recombinant protein production
Store at 4 °C. If stored properly, the product is stable for 12 months or longer.
Comparisons of Transfection Efficiency and Cytotoxicity of GenJet™ (Ver. II) with Old Version GenJet™ and Other Leading Products
Comparison of transfection efficiency (left panel) and toxicity (right panel) GenJet™ Ver. II with old version GenJet™ on commonly used mammalian cells. phRL-CMV encoding Renilla Luciferase was introduced into cells with the presence of serum and antibiotics. The Renillia Luciferase activity was determined with Renilla Luciferaase Assay System (Promega). For cytotoxicity, MTT assay was employed to determine cell viability with untransfected control as 100%.
A comparison of transfection efficiency of GenJet™ (Ver. II) vs. Lipofectamine 2000 on primary rat aortic smooth muscle cells.Primary rat aortic smooth muscle cells were prepared and transfected with a nuclear targeted GFP cDNA by GenJet™ (right panel) and Lipofectamine 2000 (L2K, left panel) respectively. The transfection efficiency were checked under a Nikon Eclipse 2000 fluorescence microscopy 48 hours post transfection
Upper Panel: Transfection efficiency comparison of GenJet™ Ver. II with old version GenJet™ on 293T cells. pEGFP-N3 was transfected to 293T cells at 90% confluency with presence of serum and antibiotics. GFP fluorescence was detected with Nikon Eclipse 2000 microscopy 48 hours post transfection
Lower panel: Transfection efficiency comparison of GenJet™ Ver. II with old version GenJet™ on Hela cells. pEGFP-N3 was transfected to Hela cells at 90% confluency with presence of serum and antibiotics. GFP fluorescence was detected with Nikon Eclipse 2000 microscopy 48 hours post transfection
Technical Information & Datasheet
- A Complete Transfection Protocol
- Protocol for Lentivirus Production
- Protocol rAAV Production
Note: All prices in US Dollars